Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation

Table 2

Linear regression models of the relation between PCZ serum concentration and treatment group and specific patient factors.

Characteristic	PCZ concentration (SE)	value
PCZ treatment group
Delayed-release tablet	1,294 (76)	<0.0001
Suspension	Reference
Age ≥ 60 years	263 (118)	0.03
Male gender	41 (117)	0.73
of >30 kg/m^2	−69 (117)	0.55
Mucositis	−352 (157)	0.03
Diarrhea	−263 (147)	0.08
Vomiting	−140 (185)	0.45
Nutrition status
Category 1	Reference
Category 2	−205 (138)	0.14
Category 3	−417 (181)	0.02
Acid suppression therapy
PPI	Reference
H2 receptor antagonist	117 (122)	0.34
None	−526 (364)	0.15

, estimated mean difference; , body mass index.